Developing a vaccine for Crimean-Congo hemorrhagic fever virus
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine
This study is working on a new vaccine to help protect people from the Crimean-Congo hemorrhagic fever virus, which is spread by ticks and can make you very sick, and they’re testing it in animals to make sure it’s safe and works well against all types of the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10867452 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine for the Crimean-Congo hemorrhagic fever virus (CCHFV), a dangerous tick-borne virus that can cause severe illness and death. The project aims to develop a recombinant vaccine using advanced techniques to ensure it is effective against all known strains of the virus. Researchers will conduct preclinical tests in animal models to evaluate the vaccine's safety and ability to provoke an immune response. The ultimate goal is to provide a viable vaccine option to protect against this high-risk pathogen.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals living in or traveling to regions where CCHFV is prevalent, particularly in Africa.
Not a fit: Patients who are not at risk of exposure to CCHFV or those who do not reside in affected areas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that protects individuals from a potentially fatal viral infection.
How similar studies have performed: Previous research has shown promise in developing vaccines for similar viral pathogens, indicating potential for success in this novel approach.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Geisbert, Thomas William — University of Texas Med Br Galveston
- Study coordinator: Geisbert, Thomas William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.